Propofol Inhibits Proliferation, Migration, Invasion and Promotes Apoptosis Through Down-Regulating miR-374a in Hepatocarcinoma Cell Lines

Liu, Shengqun; Zhang, Jingliang; Li, Zhan-Wen; Hu, Zhenhua; Liu, Zhe; Li, Yang

doi:10.1159/000493814

Cited by 33 publications

(21 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zhang et al (31) demonstrated that propofol promoted the apoptosis of cervical cancer cells by regulating the mTor signaling pathway. liu et al (32) also concluded that propofol suppressed the growth, migration and invasion of hepatocellular carcinoma cells by downregulating miRNA expression. Propofol enhanced the apoptotic effect of ddP on cervical cancer, which subsequently increased the sensitivity of cancer cells to the chemotherapeutic effect of ddP (33), whereas another study reported that propofol altered the resistance of prostate cancer cells to docetaxel by inducing hypoxia (34).…”

Section: Discussionmentioning

confidence: 99%

Propofol inhibits proliferation and cisplatin resistance in ovarian cancer cells through regulating the microRNA‑374a/forkhead box O1 signaling axis

Sun

Peng

et al. 2020

Mol Med Report

View full text Add to dashboard Cite

ovarian cancer is a prominent disease that demonstrates high incidence rates in women and often presents multidrug resistance. Propofol has been demonstrated to suppress the malignancy of various types of human cancer; however, the underlying molecular mechanisms of propofol in ovarian cancer remain largely unknown. The present study aimed to investigate whether and how propofol inhibits proliferation and cisplatin (ddP) resistance in ovarian cancer cells. ovarian cancer cell viability was assessed by the cell counting kit-8 assay; apoptosis and cell cycle progression were determined by flow cytometry; the relative expression levels of microRNA (miR)-374a and forkhead box O1 (FOXO1) were analyzed using reverse transcription-quantitative Pcr; the binding ability of miR-374a to FOXO1 was assessed by the dual-luciferase reporter assay; cellular sensitivity to ddP was detected using the MTT assay; and finally, the protein expression levels of FOXO1, p27, and Bcl-2-like-protein 11 (Bim) were analyzed by western blotting. Propofol reduced viability, promoted apoptosis and decreased mir-374a expression levels in A2780 cells. In addition, the viability of a2780/ddP cells in the propofol + ddP treatment group was significantly inhibited, and the apoptotic rate was increased. In addition, miR-374a overexpression increased cell viability and the proportion of cells in the S phase, and decreased the proportion of cells in the G0/G1 phase. conversely, genetic knockdown of miR-374a exerted the opposite effects on cell viability and cell cycle progression. Moreover, mir-374a was demonstrated to bind to FOXO1. Propofol promoted the expression of FOXO1, p27 and Bim, induced cell cycle arrest and decreased ovarian cancer cell viability. in addition, treatment with propofol and DDP regulated FOXO1 and increased apoptosis of ovarian cancer cells. in conclusion, propofol downregulated mir-374a and modulated the FOXO1 pathway to reduce proliferation and DDP resistance in ovarian cancer cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Propofol inhibits proliferation and cisplatin resistance in ovarian cancer cells through regulating the microRNA‑374a/forkhead box O1 signaling axis

Sun

Peng

et al. 2020

Mol Med Report

View full text Add to dashboard Cite

show abstract

“…Propofol also showed an inhibitory role in the adhesion of hepatocellular carcinoma cells via enhancing the expression of miR‐199a . Cell apoptosis could be induced while cell viability could be repressed by propofol through its regulations on several miRNAs including miR‐374a, miR‐24, miR‐486 and miR‐451 in different types of cancer cells . In fact, these functions of propofol were observed in numerous cancers.…”

Section: Discussionmentioning

confidence: 99%

“…8 Cell apoptosis could be induced while cell viability could be repressed by propofol through its regulations on several miRNAs including miR-374a, miR-24, miR-486 and miR-451 in different types of cancer cells. [22][23][24][25] In fact, these functions of propofol were observed in numerous cancers. Recently, pancreatic cancer malignancy was found to be suppressed by propofol via down-regulating vascular endothelial growth factor expression.…”

Section: Discussionmentioning

confidence: 99%

Propofol inhibits pancreatic cancer proliferation and metastasis by up‐regulating miR‐328 and down‐regulating ADAM8

Gao

Zhang

2019

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Propofol is commonly used for anaesthesia during surgery, and accumulating evidence has demonstrated that propofol is associated with tumour suppression. For example, propofol down‐regulates the expression of vascular endothelial growth factor to inhibit pancreatic cancer malignancy. However, deeper insights into its underlying mechanism are needed. In this study, we treated pancreatic cell lines Panc1 and Bxpc3 with or without propofol. Cell proliferation, migration and invasion were evaluated using 3‐(4,5‐Dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide and transwell assays. Real‐time polymerase chain reaction was used to measure RNA expression levels. Luciferase assay was performed to determine the transcriptional activity of microRNAs (miRNAs). We found that propofol significantly reduced the proliferation, migration and invasion of pancreatic cancer cells compared to untreated cells. By testing the changes in miRNAs after propofol treatment, propofol was shown to strikingly enhance the expression of miR‐328. Luciferase assays demonstrated that propofol repressed the transcriptional activity of miR‐328, while a disintegrin and metalloproteinase 8 (ADAM8) was a direct target of miR‐328. Knockdown of miR‐328 or ADAM8 led to significantly decreased cell growth and viability. Our results implicate that propofol inhibits pancreatic cancer growth and metastasis by enhancing miR‐328 which targets ADAM8.

show abstract

“…26 Laboratory data provide support for the effect of propofol on HCC cancer growth and survival through several different pathways. 27e29 Using human HCC cell lines, Liu and colleagues 27 reported that propofol inhibited the proliferation, migration, and invasion of HCC cells via downregulation of miR-374a. Zhang and colleagues 28 reported that propofol decreased HCC cell invasion, partly through downregulation of matrix metalloproteinase 9 (MMP-9) expression by miR-199a.…”

Section: Discussionmentioning

confidence: 99%

Propofol-based total intravenous anaesthesia is associated with better survival than desflurane anaesthesia in hepatectomy for hepatocellular carcinoma: a retrospective cohort study

Lai

Lee

Lin

et al. 2019

British Journal of Anaesthesia

View full text Add to dashboard Cite

Background: Previous studies have shown that anaesthetic technique can affect outcomes of cancer surgery. We investigated the association between anaesthetic technique and patient outcomes after elective hepatectomy for hepatocellular carcinoma. Methods: This was a retrospective single-centre cohort study of patients who received elective hepatectomy for hepatocellular carcinoma from January 2005 to December 2014. Patients were grouped according to propofol or desflurane anaesthesia. KaplaneMeier analysis was performed and survival curves were constructed from the date of surgery to death. After propensity matching, univariable and multivariable Cox regression models were used to compare hazard ratios for death. Subgroup analyses were performed for tumourenodeemetastasis staging and distant metastasis and local recurrence. Results: A total of 492 patients (369 deaths, 75.0%) with desflurane anaesthesia and 452 (139 deaths, 30.8%) with propofol anaesthesia were eligible for analysis. After propensity matching, 335 patients remained in each group. In the matched analysis, propofol anaesthesia had a better survival with hazard ratio of 0.47 (95% confidence interval, 0.38e0.59; P<0.001). Subgroup analyses also showed significantly better survival in the absence of distant metastasis (hazard ratio, 0.47; 95% confidence interval, 0.37e0.60; P<0.001) or local recurrence (hazard ratio, 0.22; 95% confidence interval, 0.14e0.34; P<0.001) in the matched groups. Conclusions: Propofol anaesthesia was associated with better survival in hepatocellular carcinoma patients who underwent hepatectomy. Prospective studies are warranted to evaluate the effects of propofol anaesthesia on surgical outcomes in hepatocellular carcinoma patients.

show abstract

Propofol Inhibits Proliferation, Migration, Invasion and Promotes Apoptosis Through Down-Regulating miR-374a in Hepatocarcinoma Cell Lines

Cited by 33 publications

References 43 publications

Propofol inhibits proliferation and cisplatin resistance in ovarian cancer cells through regulating the microRNA‑374a/forkhead box O1 signaling axis

Propofol inhibits proliferation and cisplatin resistance in ovarian cancer cells through regulating the microRNA‑374a/forkhead box O1 signaling axis

Propofol inhibits pancreatic cancer proliferation and metastasis by up‐regulating miR‐328 and down‐regulating ADAM8

Propofol-based total intravenous anaesthesia is associated with better survival than desflurane anaesthesia in hepatectomy for hepatocellular carcinoma: a retrospective cohort study

Contact Info

Product

Resources

About